Messenger RNA (mRNA) therapeutics have moved from a promising idea to clinical reality, accelerating vaccine development and opening new paths ...

A research team from The Hong Kong University of Science and Technology (HKUST) has made a breakthrough discovery in understanding the molecular ...

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines in areas of high unmet need in rare muscle diseases, ...

Dyne Therapeutics' Z-basivarsen led to gains in motor function and cognition for myotonic dystrophy type 1, and is entering a ...

Acurastem received a grant to develop ALS therapies targeting SYF2, a regulator of TDP-43, in collaboration with academic research teams.

Paul Conyngham, an Australian technology enthusiast, developed a custom mRNA vaccine for his cancer-stricken dog, Rosie.

Barclays 28th Annual Global Healthcare Conference March 12, 2026 8:30 AM EDTCompany ParticipantsAmy Parison - Senior VP ...

Researchers created long noncoding RNA targeting inflammatory pathways. The approach reduced cytokine production in human cell cultures and mouse models, demonstrating a novel strategy for RNA-based ...

Explore the breakthrough of lab-made lncRNA by University of Toronto Engineering for new drug discovery potential.

Christine Dunham is a leading expert on the ribosome—an elaborate macro-molecular machine that operates like a factory within ...

The administration had cut crucial funding for mRNA-based therapies. The rest of the world might step in and benefit.